APA (7th ed.) Citation

ME, C., V, C., E, R., I, P., F, B., G, M., . . . S, C. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: Real-world data from the HERMIONE-13 study. ESMO real world data and digital oncology, 11, 100665. https://doi.org/10.1016/j.esmorw.2025.100665

Chicago Style (17th ed.) Citation

ME, Cazzaniga, et al. "Second-line Therapies After CDK4/6 Inhibitor Failure in HR-positive/HER2-negative Metastatic Breast Cancer Patients: Real-world Data from the HERMIONE-13 Study." ESMO Real World Data and Digital Oncology 11 (2026): 100665. https://doi.org/10.1016/j.esmorw.2025.100665.

MLA (9th ed.) Citation

ME, Cazzaniga, et al. "Second-line Therapies After CDK4/6 Inhibitor Failure in HR-positive/HER2-negative Metastatic Breast Cancer Patients: Real-world Data from the HERMIONE-13 Study." ESMO Real World Data and Digital Oncology, vol. 11, 2026, p. 100665, https://doi.org/10.1016/j.esmorw.2025.100665.